Year : 2026 | Volume : 13 | 02 | Page :

Siya Vijaykumar Chawhan,

Sayali Manoj Sayare,

Rukmini Sankar Girhepunje,

Tilottama Moreshwar Gatkine,

Student, Department of Pharmaceutics, Nagpur College of Pharmacy, Hingna, Wanadongri, 441110, Maharashtra, India
Assistant Professor, Department of Pharmaceutics, Nagpur College of Pharmacy, Hingna, Wanadongri, 441110, Maharashtra, India
Assistant Professor, Department of Pharmaceutics, Nagpur College of Pharmacy, Hingna, Wanadongri, 441110, Maharashtra, India
Assistant Professor, Department of Pharmaceutics, Nagpur College of Pharmacy, Hingna, Wanadongri, 441110, Maharashtra, India

Abstract

Intranasal drug delivery has gained considerable attention as a non-invasive route for delivering drugs to both systemic circulation and the central nervous system, particularly for the treatment of migraine. Traditional nasal formulations such as sprays and drops often show poor therapeutic performance due to rapid mucociliary clearance and limited retention within the nasal cavity. To overcome these challenges, in-situ gel systems have been designed, which transform from a liquid to a gel state under physiological conditions, thereby improving residence time and drug absorption. pH-responsive in-situ nasal gels are especially advantageous as they undergo gelation at the physiological pH of the nasal cavity, resulting in enhanced mucoadhesion and prolonged drug release. The present review provides a critical overview of recent developments (2020–2025) in pH-triggered nasal gel systems with particular relevance to migraine therapy. Special attention is given to herbal therapeutic agents such as ginger extract and peppermint oil, which possess notable anti-inflammatory and analgesic activities. In addition, the capability of these systems to facilitate direct nose-to-brain drug transport via olfactory and trigeminal pathways is discussed, emphasizing their significance in improving brain targeting efficiency. Although these systems show promising potential, certain limitations such as formulation stability, variability in herbal components, and lack of extensive clinical validation still exist. Therefore, further research is required to fully establish their clinical applicability. Overall, pH-responsive in-situ nasal gels containing herbal actives offer a promising approach for effective migraine management. This review uniquely emphasizes the integration of herbal therapeutics such as ginger extract and peppermint oil with pH-triggered nasal gel systems, an area that remains relatively underexplored in current pharmaceutical research.

Keywords: Intranasal drug delivery, pH-responsive in-situ gel, Nose-to-brain delivery, Migraine therapy, Ginger extract, Peppermint oil, Mucoadhesive polymers.

How to cite this article:
Siya Vijaykumar Chawhan, Sayali Manoj Sayare, Rukmini Sankar Girhepunje, Tilottama Moreshwar Gatkine. pH-Triggered In-Situ Nasal Gel Systems for Migraine Therapy: A Review. Trends in Drug Delivery. 2026; 13(02):-.

How to cite this URL:
Siya Vijaykumar Chawhan, Sayali Manoj Sayare, Rukmini Sankar Girhepunje, Tilottama Moreshwar Gatkine. pH-Triggered In-Situ Nasal Gel Systems for Migraine Therapy: A Review. Trends in Drug Delivery. 2026; 13(02):-. Available from: https://journals.stmjournals.com/tdd/article=2026/view=246697

References

1. L I. Nasal drug delivery—possibilities, problems and solutions. J Control Release. 2003;: 187–198.
2. Costantino HR ILBGJPQS. Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm. 2007;: 1–24.
3. S G. Anatomical and histological factors affecting intranasal drug delivery. Curr Drug Deliv. 2012;: 566–582.
4. PG D. Nasal drug delivery devices: characteristics and performance. Drug Deliv Transl Res. 2013;: 42–62.
5. Hanson LR FW. Intranasal delivery bypassing the blood–brain barrier. BMC Neurosci. 2008.
6. Dhuria SV HLFW. Intranasal delivery to the CNS: and experimental considerations. J Pharm Sci. 2010;: 1654–1673.
7. Lochhead JJ TR. Intranasal delivery of biologics to the CNS. Adv Drug Deliv Rev. 2012;: 614–628.
8. WM P. The blood– mechanisms brain barrier: bottleneck in brain drug development. NeuroRx. 2005;: 3–14.
9. Goadsby PJ HPMOMHJSCAS. Pathophysiology of migraine. Physiol Rev. 2017;: 553–622.
10. SJ T. Triptans and migraine therapy: clinical review. Headache. 2013;: 1–14.
11. Peppas NA BPLWIH. Hydrogels in pharmaceutical formulations. Eur J Pharm Biopharm. 2000;: 27–46.
12. Koetting MC PJSSPN. Stimulus-responsive hydrogels. Mater Sci Eng R Rep. 2015;: 1–49.
13. Alshraim A ea. In situ thermosensitive mucoadhesive nasal gel containing sumatriptan. Polymers. 2024;: 3422.
14. Ghazwani M ea. Intranasal thermotriggered in situ gel containing mirtazapine. Gels. 2023;: 457.
15. Suhagiya K ea. Mucoadhesive in situ nasal gel for rizatriptan. Results in Chemistry. 2023.
16. Tanna V ea. Nose-to-brain nano delivery for migraine. Curr Drug Deliv. 2023.
17. Liu DH CHWB. Anatomy and physiology of the nasal valves. Otolaryngol Clin North Am. 2025;: 189–203.
18. Wexler DB DT. The nasal valve: anatomy, imaging, and physiology. Am J Rhinol. 2004;: 143–150.
19. Sobiesk JL MS. Anatomy, Head and Neck, Nasal Cavity. StatPearls Publishing. 2023.
20. RL D. Olfactory system function and structure. Handb Clin Neurol. 2019;: 3–21.
21. S G. Anatomical and histological factors affecting intranasal drug delivery. Curr Drug Deliv. 2012;: 566–582.
22. Ozsoy Y ea. Transcellular transport mechanisms for drug delivery. Front Pharmacol. 2022.
23. Arora P ea. Intranasal drug delivery: mechanisms and barriers. Pharmaceutics. 2024.
24. Maeng J LK. Intranasal delivery to the brain using transport pathways. Front Pharmacol. 2022;: 1068495.
25. Jung Soo Koo ea. Recent advances in intranasal administration for brain-targeting delivery. Int J Nanomedicine. 2024;: 1767–1807.
26. Ghadiri M YPTD. Strategies to enhance drug absorption via nasal and pulmonary routes. Pharmaceutics. 2019;: 113.
27. Aderibigbe BA. Nose-to-brain delivery: current approaches and challenges. Pharmaceutics. 2022;: 2719.
28. Jung Soo Koo ea. Recent advances in intranasal administration for brain-targeting delivery. Int J Nanomedicine. 2024;: 1767–1807.
29. Gänger S SK. Tailoring formulations for intranasal nose-to-brain delivery. J Control Release. 2021;: 586–603.
30. Mehta K ea. Nano-gel systems for CNS drug delivery. Colloids Surf B Biointerfaces. 2023.
31. Nair AB ea. Advances in in-situ gelling systems for nasal delivery. Pharmaceutics. 2022;: 1023.
32. Bansal S ea. Chitosan-based mucoadhesive nasal delivery systems. Carbohydr Polym. 2022;: 118130.
33. Wei S ZZKXea. The review of nasal drug delivery system: strategies to enhance intranasal drug absorption. Int J Pharm. 2025;: 125584.
34. Keller LA MOPA. Intranasal drug delivery: opportunities and toxicologic challenges during drug development. Drug Deliv Transl Res. 2022;: 735–757.
35. Touitou E IL. Nasal drug delivery. Drug Deliv Transl Res. 2013;: 1–3.
36. Erdő F BLFDBÁGS. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res Bull. 2018;: 155–170.
37. al PAe. Development of intranasal in situ gel systems: formulation challenges and strategies. Asian J Pharm Res Dev. 2026;: 45–55.
38. al AMe. Nose-to-brain delivery: current challenges and future perspective. Pharmaceutics. 2023;: 456.
39. Pardeshi CV BV. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood–brain barrier. Drug Delivery. 2013;: 292–301.
40. Jiang L GLWXTLMJ. The application of mucoadhesive polymers in nasal drug delivery. Drug Development and Industrial Pharmacy. 2010;: 323–336.
41. Chaturvedi M KMPK. A review on mucoadhesive polymer used in nasal drug delivery system. J Adv Pharm Technol Res. 2011;: 215–222.
42. Singh RM KAPK. Mucoadhesive in situ nasal gelling drug delivery systems for modulated drug delivery. Expert Opin Drug Deliv. 2013;: 115–130.
43. Porfiryeva NN MRKV. Advances in mucoadhesive and mucus-penetrating materials for nasal drug delivery. Expert Opin Drug Deliv. 2026.
44. Kulkarni AD ea. Thermosensitive in situ gels for nasal drug delivery. Drug Delivery and Translational Research. 2020;: 1316–1335.
45. Patel RB ea. pH-triggered in situ gel systems for controlled drug delivery. International Journal of Pharmaceutics. 2022;: 121543.
46. Kulkarni AD ea. Thermosensitive in situ gels for nasal drug delivery. Drug Delivery and Translational Research. 2020;: 1316–1335.
47. Morsi N ea. Ion-sensitive in situ gels for intranasal drug delivery. Pharmaceutics. 2021;: 405.
48. Sharma PK CMea. In situ gel systems for nasal drug delivery: A review. Journal of Drug Delivery Science and Technology. 2021;: 102440.
49. Liu Y ZJWYea. Recent advances in stimuli-responsive in situ gelling systems for drug delivery. European Journal of Pharmaceutics and Biopharmaceutics. 2023;: 1–18.
50. Kaur G PAea. Advances in nasal in situ gel formulations for brain targeting. Drug Delivery. 2022;: 3120–3135.
51. Abdelrahman AA ea. Development of pH-triggered in situ gelling system for nasal delivery. Pharmaceutics. 2024.
52. N.A. Peppas BPLWIH. Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm. 2007;: 1–24.
53. A.V. Pawar ea. Carbopol-based in situ gel systems for nasal drug delivery. Drug Deliv. 2011;: 441–448.
54. Shah RA MMPD. Design and optimization of mucoadhesive nasal in situ gel. Asian J Pharm. 2024.
55. Park K. Controlled drug delivery systems: past forward and future back. J Control Release. 2014;: 3–8.
56. V.R. Sinha KR. Polysaccharides in colon-specific drug delivery. Int J Pharm. 2001;: 19–38.
57. Balakrishnan P ea. Carbopol-based gels for nasal drug delivery. Molecules. 2015;: 4124–4135.
58. Shah VP ea. Development of mucoadhesive nasal gel. Asian J Pharm. 2014.
59. Wang M MXZSea. The prescription design and key properties of nasal gel for CNS drug delivery: A review. Eur J Pharm Sci. 2023.
60. Salamah M ea. Development and characterization of in situ gelling nasal formulation. Pharmaceutics. 2025.
61. Qian L ea. In situ gels for nasal drug delivery: formulation strategies and applications. Macromol Mater Eng. 2025.
62. Mardikasari SA ea. Mucoadhesive in situ nasal gel for improved drug retention. Eur J Pharm Sci. 2024.
63. Ge Y ea. Nasal drug delivery and nose-to-brain delivery: current status and future perspectives. Pharmaceutics. 2024.
64. Gandhi S ea. Nasal delivery to the brain: advancements and opportunities. Pharmaceutics. 2024.
65. Wei S ea. Strategies to improve nasal drug delivery systems. Int J Pharm. 2025.
66. Rai G ea. Advances in nanotechnology for intranasal drug delivery. Eur J Pharm Sci. 2023.
67. Wang M MXZSea. Design and evaluation of nasal gels for CNS delivery. Eur J Pharm Sci. 2023.
68. AG B. Physiology and pathophysiology of nasal mucosa. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2010.
69. England RJ ea. Nasal pH and its role in drug absorption. Rhinology. 2000.
70. Deshkar S ea. Rheological characterization of in situ gels. Polymers. 2023.
71. Singh R ea. Evaluation of viscosity and flow behavior in nasal gels. J Drug Deliv Sci Technol. 2024;: 105234.
72. Khan S ea. Stimuli-responsive in situ gels: formulation and evaluation. Polymers. 2022;: 500.
73. Andrews GP ea. Mucoadhesive polymeric platforms. Eur J Pharm Biopharm. 2009;: 505–518.
74. Mardikasari SA ea. Mucoadhesive nasal gel formulation study. Eur J Pharm Sci. 2024;: 106897.
75. Q2(R2) I. Validation of analytical procedures. ICH Guidelines. 2023.
76. Blessy M ea. Stability indicating methods in pharmaceuticals. J Pharm Anal. 2014;: 159–165.
77. Patel A ea. In vitro release testing of nasal gels using Franz diffusion cells. Int J Pharm. 2023;: 122910.
78. Costa P LJ. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;: 123–133.
79. Dhuria SV HLFW. Intranasal delivery to CNS. J Pharm Sci. 2010;: 1654–1673.
80. Koo J LCOK. Intranasal delivery systems for brain targeting. Int J Nanomedicine. 2024.
81. Q1A(R2) I. Stability testing of new drug substances and products. 2023.
82. Pavčnik L ea. Accelerated predictive stability testing in pharmaceuticals. Pharmaceutics. 2025.
83. Hussain Z ea. Safety evaluation of intranasal drug delivery systems: current status and future perspectives. Pharmaceutics. 2023;: 2315.
84. Gandhi S ea. Advances in intranasal delivery for CNS targeting. 10.3390/pharmaceutics16050678. 2024;: 678.
85. Chella S KS. Formulation and evaluation of nasal in situ gel for enhanced drug delivery. Adv Pharmacol Pharm. 2025;: 713–720.
86. Koo J LCOK. Recent advances in intranasal delivery for brain targeting. Int J Nanomedicine. 2024;: 2345–2365.
87. Mittal D ea. Nanocarrier-based approaches for intranasal drug delivery. Drug Deliv Transl Res. 2024.
88. L I. Recent advances in nasal drug delivery systems. J Control Release. 2023;: 101–120.
89. Shim S YH. The application of mucoadhesive chitosan nanoparticles in nasal drug delivery. Mar Drugs. 2020;: 605.
90. Chaturvedi M KMPK. A review on mucoadhesive polymer used in nasal drug delivery system. J Adv Pharm Technol Res. 2011;: 215–222.
91. Agrawal M SSSSea. Stimuli-responsive in situ gelling system for nose-to-brain drug delivery. Journal of Controlled Release. 2020;: 235–265.
92. BA A. In situ-based gels for nose-to-brain delivery for the treatment of neurological diseases. Pharmaceutics. 2018;: 40.
93. Alkufi HK KH. Formulation and evaluation of sustained release sumatriptan mucoadhesive intranasal in-situ gel. Iraqi Journal of Pharmaceutical Sciences. 2019;: 95–104.
94. Chen L. CZ. The efficacy of ginger for the treatment of migraine: A meta-analysis of randomized controlled studies. American Journal of Emergency Medicine. 2021;: 10.1016/j.ajem.2020.11.030.
95. al MLBe. Double-blind placebo-controlled randomized clinical trial of ginger in migraine treatment. Cephalalgia. 2019;: 68–75.
96. Baloglu E. KSY. Formulation and evaluation of thermoresponsive in situ nasal gel. AAPS PharmSciTech. 2009;: 784–791.
97. Baloglu E KS. Formulation and evaluation of thermoresponsive in situ nasal gel. AAPS PharmSciTech. 2009;: 784–791.
98. Chatterjee S ea. Evaluation of Carbopol composite mucoadhesive hydrogel on pharmaceutical performance. International Journal of Biological Macromolecules. 2025;: 138708.
99. L I. Nasal drug delivery—recent developments and future prospects. Journal of Controlled Release. 2012;: 254–263.
100. Safarov S ea. Advances in intranasal drug delivery systems for brain targeting. Pharmaceutics. 2024;: 345.
101. Patel D ea. pH-sensitive in-situ nasal gel of rizatriptan: formulation and evaluation. AAPS PharmSciTech. 2023;: 150.
102. Ahmad N ea. Herbal-based intranasal drug delivery systems: opportunities and challenges. Journal of Drug Delivery Science and Technology. 2022;: 103456.

Ahead of Print Subscription Review Article

Trends in Drug Delivery

ISSN: 2394-7268

Volume	13
	02
Received	01/06/2026
Accepted	12/06/2026
Published	14/06/2026
Publication Time	13 Days

Login

PlumX Metrics

Initiatives

Legal Information

Contact Us

STM Journals
An imprint of Consortium E-learning network Pvt. Ltd.
A-118, 1st Floor, Sector-63, Noida, U.P. India, Pin-201301
(Tel) (+91) 0120- 4781 200
(Mob) (+91) 9810078958, +919667725932
[email protected]

Join Us

Submit Manuscript

Submit Topics

WEBSITE DISCLAIMER

Last updated: 2022-06-15

The information provided by STM Journals (“Company”, “we”, “our”, “us”) on https://journals.stmjournals.com/ (the “Site”) is for general informational purposes only. All information on the Site is provided in good faith, however, we make no representation or warranty of any kind, express or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any information on the Site.

UNDER NO CIRCUMSTANCE SHALL WE HAVE ANY LIABILITY TO YOU FOR ANY LOSS OR DAMAGE OF ANY KIND INCURRED AS A RESULT OF THE USE OF THE SITE OR RELIANCE ON ANY INFORMATION PROVIDED ON THE SITE. YOUR USE OF THE SITE AND YOUR RELIANCE ON ANY INFORMATION ON THE SITE IS SOLELY AT YOUR OWN RISK.

EXTERNAL LINKS DISCLAIMER

The Site may contain (or you may be sent through the Site) links to other websites or content belonging to or originating from third parties or links to websites and features. Such external links are not investigated, monitored, or checked for accuracy, adequacy, validity, reliability, availability, or completeness by us.

WE DO NOT WARRANT, ENDORSE, GUARANTEE, OR ASSUME RESPONSIBILITY FOR THE ACCURACY OR RELIABILITY OF ANY INFORMATION OFFERED BY THIRD-PARTY WEBSITES LINKED THROUGH THE SITE OR ANY WEBSITE OR FEATURE LINKED IN ANY BANNER OR OTHER ADVERTISING. WE WILL NOT BE A PARTY TO OR IN ANY WAY BE RESPONSIBLE FOR MONITORING ANY TRANSACTION BETWEEN YOU AND THIRD-PARTY PROVIDERS OF PRODUCTS OR SERVICES.

PROFESSIONAL DISCLAIMER

The Site can not and does not contain medical advice. The information is provided for general informational and educational purposes only and is not a substitute for professional medical advice. Accordingly, before taking any actions based on such information, we encourage you to consult with the appropriate professionals. We do not provide any kind of medical advice.

Content published on https://journals.stmjournals.com/ is intended to be used and must be used for informational purposes only. It is very important to do your analysis before making any decision based on your circumstances. You should take independent medical advice from a professional or independently research and verify any information that you find on our Website and wish to rely upon.

THE USE OR RELIANCE OF ANY INFORMATION CONTAINED ON THIS SITE IS SOLELY AT YOUR OWN RISK.

AFFILIATES DISCLAIMER

The Site may contain links to affiliate websites, and we may receive an affiliate commission for any purchases or actions made by you on the affiliate websites using such links.

TESTIMONIALS DISCLAIMER

The Site may contain testimonials by users of our products and/or services. These testimonials reflect the real-life experiences and opinions of such users. However, the experiences are personal to those particular users, and may not necessarily be representative of all users of our products and/or services. We do not claim, and you should not assume that all users will have the same experiences.

YOUR RESULTS MAY VARY.

The testimonials on the Site are submitted in various forms such as text, audio, and/or video, and are reviewed by us before being posted. They appear on the Site verbatim as given by the users, except for the correction of grammar or typing errors. Some testimonials may have been shortened for the sake of brevity, where the full testimonial contained extraneous information not relevant to the general public.

The views and opinions contained in the testimonials belong solely to the individual user and do not reflect our views and opinions.

ERRORS AND OMISSIONS DISCLAIMER

While we have made every attempt to ensure that the information contained in this site has been obtained from reliable sources, STM Journals is not responsible for any errors or omissions or the results obtained from the use of this information. All information on this site is provided “as is”, with no guarantee of completeness, accuracy, timeliness, or of the results obtained from the use of this information, and without warranty of any kind, express or implied, including, but not limited to warranties of performance, merchantability, and fitness for a particular purpose.

In no event will STM Journals, its related partnerships or corporations, or the partners, agents, or employees thereof be liable to you or anyone else for any decision made or action taken in reliance on the information in this Site or for any consequential, special or similar damages, even if advised of the possibility of such damages.

GUEST CONTRIBUTORS DISCLAIMER

This Site may include content from guest contributors and any views or opinions expressed in such posts are personal and do not represent those of STM Journals or any of its staff or affiliates unless explicitly stated.

LOGOS AND TRADEMARKS DISCLAIMER

All logos and trademarks of third parties referenced on https://journals.stmjournals.com/ are the trademarks and logos of their respective owners. Any inclusion of such trademarks or logos does not imply or constitute any approval, endorsement, or sponsorship of STM Journals by such owners.

Use of AI Tools in Blog Content

Some of the blog posts published on this website are created with the assistance of Artificial Intelligence (AI) tools. While efforts are made to review and edit the content for accuracy and appropriateness, there may still be instances where unintended, unnecessary, or unverified information or claims appear.Readers are advised to use their discretion while interpreting the content. The primary purpose of using AI-generated content is to provide our audience with the most recent, diverse, and wide-ranging information on various topics. The content is intended to inform and engage, not to mislead.All external links included in the blogs are intended to guide users to real and authentic workshops, programs, or resources. The information presented through those links is curated and verified to the best of our knowledge.This disclaimer is meant to inform visitors about the use of AI in content creation, acknowledge potential limitations in content accuracy, and encourage informed and responsible reading.

CONTACT US

Should you have any feedback, comments, requests for technical support, or other inquiries, please contact us by email: [email protected].